Erschienen in:
07.05.2020 | Pharmacology and Pharmacodynamics of Antifungal Agents (J Amsden, Section Editor)
Antifungal and Oral Anticancer Therapy Drug Interactions
verfasst von:
Chelsea Gustafson, Molly Koslosky, Jill Leslie, Christopher Walczak
Erschienen in:
Current Fungal Infection Reports
|
Ausgabe 2/2020
Einloggen, um Zugang zu erhalten
Abstract
Purpose of Review
In the past 5 years, there has been a significant expansion in the oncology arsenal. These new oncolytic therapies are being incorporated with traditional cytotoxic chemotherapy or used as single-agent therapy. Disease states such as acute and chronic leukemias have seen some the largest therapy expansion in decades. Frequently, these patients often necessitate the use of antifungals in either the prophylaxis or treatment setting. This review provides a brief overview of recently approved oncolytic therapies and the drug-drug interactions (DDIs) that clinicians encounter when managing antifungal therapies.
Recent Findings
DDIs between the newer oncolytic and systemic azole antifungals frequently exist and require treatment modification or use of alternative antifungal therapies. Recent literature and center specific evaluations of antifungal therapy and oral chemotherapy drug interactions are reviewed.
Summary
As the oncolytic arsenal has expanded treatment options for cancer patients, it is important for clinicians to be aware of significant DDIs and the potential impact on treatment.